Takacs Michael1Frass Michael2Walder Gernot3Fibert Philippa4Rottensteiner Maria5Glück Walter5Lechleitner Peter1Oberbaum Menachem6Leisser Ilse7Chandak Kavita8Panhofer Peter9Weiermayer Petra10

Complement Ther Clin Pract. 2021 May 11;44:101415. doi: 10.1016/j.ctcp.2021.101415. Online ahead of print.


Background: and purpose. COVID-19 is a novel viral disease causing worldwide pandemia. The aim of this study was to describe the effect of adjunctive individualized homeopathic treatment delivered to hospitalized patients with confirmed symptomatic SARS-CoV-2 infection.

Patient presentation: Thirteen patients with COVID-19 were admitted. Mean age was 73.4 ± 15.0 (SD) years. Twelve (92.3%) were speedily discharged without relevant sequelae after 14.4 ± 8.9 days. A single patient admitted in an advanced stage of septic disease died in hospital. A time-dependent improvement of relevant clinical symptoms was observed in the 12 surviving patients. Six (46.2%) were critically ill and treated in the intensive care unit (ICU). Mean stay at the ICU of the 5 surviving patients was 18.8 ± 6.8 days. In six patients (46.2%) gastrointestinal disorders accompanied COVID-19.

Conclusion: The observations suggest that adjunctive homeopathic treatment may be helpful to treat patients with confirmed COVID-19 even in high – risk patients especially since there is no conventional treatment of COVID-19 available at present.

Keywords: COVID-19; Complementary therapies; Homeopathy; Intensive care unit; SARS-CoV-2.

Links: PMID: 33989861; PMCID: PMC8110319; DOI: 10.1016/j.ctcp.2021.101415